Reported 2 days ago
Alkermes plc (NASDAQ:ALKS) has been highlighted as one of the top small-cap stock picks by billionaire Jim Simons' Renaissance Technologies, showcasing a notable upside potential of 35.04%. The Irish biopharmaceutical company, which focuses on treatments for mental health, neurological conditions, and cancer, reported impressive financial results for 2024, with a total revenue of $1.56 billion. Despite recent market challenges and a price target adjustment from UBS, Alkermes remains a compelling investment option amid a growing addiction treatment market.
Source: YAHOO